Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Risk_Evaluation_and_Mitigation_Strategy_program
|
| gptkbp:administeredBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:appliesTo |
gptkb:Accutane
gptkb:isotretinoin gptkb:Absorica gptkb:Amnesteem gptkb:Claravis gptkb:Myorisan gptkb:Sotret gptkb:Zenatane |
| gptkbp:criticizedFor |
complexity
technical issues gendered language access barriers |
| gptkbp:purpose |
prevent fetal exposure to isotretinoin
|
| gptkbp:relatedTo |
gptkb:acne_treatment
dermatology teratogenicity prevention |
| gptkbp:requires |
limited prescription window
monthly counseling registration of patients registration of pharmacies registration of prescribers monthly pregnancy tests for patients who can become pregnant use of two forms of contraception for patients who can become pregnant |
| gptkbp:startDate |
March 2006
|
| gptkbp:updated |
December 2021
|
| gptkbp:website |
https://www.ipledgeprogram.com
|
| gptkbp:bfsParent |
gptkb:Accutane
gptkb:isotretinoin |
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
iPLEDGE
|